Furthermore, 89% of anti–TIF1-γ–positive patients with anti-CCAR1 antibodies were diagnosed at stage 0 or 1, which contrasts with 42% of anti–TIF1-γ–positive DM patients without anti-CCAR1 antibodies, who largely presented with more advanced cancers. Here, CCAR1 is linked to cancer.